Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis
| Autor: | Dima Hnoosh, Bin Huang, Hayder Saeed, Sean P. Dineen, Lowell B. Anthony, Ching Wei D. Tzeng, Peter J. Hosein, Philip A. DeSimone, Erin Maynard, Eric B. Durbin, Patrick C. McGrath |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Multivariate analysis business.industry medicine.medical_treatment General Medicine medicine.disease Surgery Cancer registry 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Pancreatic cancer Pancreatectomy medicine Adjuvant therapy Adenocarcinoma Combined Modality Therapy 030212 general & internal medicine Stage (cooking) business |
| Zdroj: | Journal of Surgical Oncology. 114:451-455 |
| ISSN: | 0022-4790 |
| Popis: | Background Long-term results of the ESPAC-3 trial suggest that while completing adjuvant therapy (AT) is necessary after resection of pancreatic ductal adenocarcinoma (PDAC), early initiation (within 8 weeks) may not be associated with improved overall survival (OS). The primary aim of this study was to evaluate the OS impact of early versus late AT in a statewide analysis. Methods Patients with stages I–III PDAC in the Kentucky Cancer Registry (KCR) from 2004 to 2013, were evaluated. Those undergoing pancreatectomy were stratified into two groups (“early,” |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text